850-876-4735
SCHEDULE AN APPOINTMENT

Genitourinary Syndrome of Menopause and BHRT: Symptoms, Causes, and Treatment Options

Oct 27 2026 | By: Casey Posey, MSN, APRN-BC at Glow Health and Wellness

Smiling woman sitting on a bed beside a text panel about genitourinary syndrome of menopause and birth control options

Genitourinary Syndrome of Menopause and BHRT: Symptoms, Causes, and Treatment Options

A patient-centered guide to recognizing GSM, understanding its hormonal roots, and exploring how personalized bioidentical hormone replacement therapy can restore comfort and quality of life

Many women move through the menopausal transition focusing on hot flashes, sleep disruption, or mood changes, only to discover that quieter but persistent changes in the genital and urinary areas begin to affect daily comfort, intimacy, and confidence. These changes are not simply a normal part of aging that must be endured. They form a recognized clinical condition called genitourinary syndrome of menopause, or GSM. At Glow Health and Wellness, we see how often these symptoms go unspoken because of embarrassment or the mistaken belief that nothing can be done. This post explains what GSM is, why it develops, how it shows up in everyday life, and how thoughtfully prescribed bioidentical hormone replacement therapy, along with supportive measures, can bring meaningful relief.

What Is Genitourinary Syndrome of Menopause

Genitourinary syndrome of menopause describes the collection of symptoms and physical changes that occur in the vulva, vagina, and lower urinary tract when estrogen and other sex hormones decline. The term was introduced in 2014 by leading menopause and sexual health organizations to replace older labels such as vulvovaginal atrophy. Those earlier names felt incomplete and carried negative connotations for many women. GSM better captures the full picture because the same tissues that form the genital tract also form parts of the bladder and urethra, so hormonal shifts affect both areas.

Unlike hot flashes that often improve over time, GSM tends to progress if left unaddressed. The tissues gradually lose thickness, elasticity, blood flow, and natural moisture. Vaginal pH rises, the protective balance of healthy bacteria shifts, and the supportive connective tissue weakens. These changes can appear during perimenopause, after natural menopause, following surgical removal of the ovaries, or during any prolonged period of low estrogen, including certain medical treatments. Recognizing GSM as a treatable condition rather than an inevitable consequence of aging opens the door to effective care.

Recognizing the Symptoms of GSM

Symptoms of genitourinary syndrome of menopause fall into three overlapping categories: genital, urinary, and sexual. Genital symptoms often include persistent dryness, burning, itching, or irritation of the vulva and vagina. Some women notice a feeling of pressure, thinning of the labia, or a sense that the tissues feel fragile. Discharge may change, and small tears or spotting can occur with everyday activity or friction.

Urinary symptoms commonly involve urgency, frequency, a sudden need to void, discomfort with urination, or recurrent urinary tract infections that seem to return without clear bacterial causes. Nighttime trips to the bathroom may increase. Some women experience leakage with urgency or with activity. These urinary changes arise because the bladder and urethra also depend on adequate estrogen for healthy lining, muscle tone, and sensory function.

Sexual symptoms frequently include reduced natural lubrication, pain with penetration, post-activity bleeding or discomfort, and difficulty with arousal or orgasm. Desire may decline not only from hormonal shifts but also from the anticipation of discomfort. Many women describe a progressive cycle in which less frequent intimacy leads to further tissue changes, which then makes intimacy more difficult. Symptoms can vary in intensity from mild inconvenience to significant interference with daily life and relationships. Because the condition is progressive, early recognition allows more effective intervention.

Understanding the Causes Behind GSM

The primary driver of genitourinary syndrome of menopause is the sharp decline in estrogen that accompanies the end of ovarian function. Estrogen receptors are abundant throughout the vaginal epithelium, vulvar tissues, urethra, and bladder trigone. When circulating estrogen falls, these receptors receive far less stimulation. The outer layers of the vaginal lining thin, blood vessels diminish, collagen production decreases, and elastic fibers fragment. Natural lubrication declines because the glands and tissues that produce moisture no longer receive the hormonal signal they need.

Androgen levels also fall with age and after menopause, and androgen receptors are present in the same tissues. Reduced androgen activity contributes to changes in muscle tone, collagen, and sexual response. The vaginal microbiome shifts as glycogen content drops, lactobacilli decrease, and pH rises toward a more neutral or alkaline range. This altered environment favors irritation and recurrent infections.

Additional factors can accelerate or intensify these changes. Surgical menopause produces an abrupt drop in hormones. Certain cancer treatments that suppress estrogen, prolonged breastfeeding, or conditions that cause premature ovarian insufficiency can produce similar tissue effects at younger ages. Smoking, lack of sexual activity or vaginal stretching, and some medications may worsen symptoms. The process is not purely chronological aging. It is a hormone-dependent change that responds when the underlying deficiency is addressed.

How GSM Affects Daily Life and Relationships

The impact of genitourinary syndrome of menopause often extends beyond physical discomfort. Persistent dryness or burning can make sitting, walking, or wearing certain clothing uncomfortable. Recurrent urinary symptoms disrupt sleep and create anxiety about being near a restroom. Painful intimacy can strain partnerships, reduce emotional closeness, and lower self-esteem. Many women report feeling less feminine or less connected to their bodies.

Because symptoms develop gradually, some women adapt by avoiding intimacy, using extra protection for leakage, or limiting activities. Others seek repeated courses of antibiotics for urinary symptoms without addressing the underlying tissue changes. The emotional toll includes frustration, embarrassment, and a sense of isolation, especially when friends or providers minimize the concerns. Quality of life studies consistently show that untreated GSM affects sexual function, relationship satisfaction, and overall well-being. The good news is that effective options exist, and addressing the hormonal foundation often brings relief that improves multiple areas of life at once.

The Role of Bioidentical Hormone Replacement Therapy in Managing GSM

Bioidentical hormone replacement therapy uses hormones that are chemically identical to those produced by the human body. For genitourinary syndrome of menopause, the most relevant hormones are estradiol and, in some cases, related compounds that support tissue health. When GSM is the primary concern and systemic menopausal symptoms are mild or absent, low-dose local vaginal estrogen delivered as a cream, tablet, insert, or ring is often highly effective. These preparations restore thickness, moisture, elasticity, and a healthier pH with minimal absorption into the bloodstream.

For women who also experience hot flashes, night sweats, sleep disruption, or other systemic symptoms, carefully dosed systemic bioidentical estradiol, combined with micronized progesterone, can improve both sets of symptoms. Women can benefit from the addition of testosterone or other supportive hormones when clinical evaluation and laboratory findings indicate a need. The goal is not simply to raise a lab number. The goal is to restore tissue integrity, reduce symptoms, and support overall well-being through individualized dosing, route of administration, and ongoing monitoring.

Local therapy does not typically require concurrent progesterone for endometrial protection because systemic absorption remains very low. Systemic therapy follows established principles of balancing estrogen with progesterone when indicated. At Glow Health and Wellness we emphasize shared decision-making, thorough history, appropriate laboratory assessment when helpful, and regular follow-up so that therapy remains aligned with each woman’s goals and health profile.

Local and Systemic Treatment Approaches with BHRT

Local low-dose vaginal estrogen remains a cornerstone of care for genitourinary syndrome of menopause. Creams allow flexible dosing and can be applied to both vaginal and external tissues. Tablets and softgel inserts offer convenience with measured doses. Clinical evidence shows consistent improvement in dryness, discomfort, and dyspareunia, along with reductions in recurrent urinary tract infections for many women. Symptom relief often begins within weeks, though full tissue restoration may take one to three months of consistent use. Continued therapy is usually needed because symptoms tend to return if treatment stops.

Choice of preparation, dose, and duration is guided by symptom severity, response to prior treatments, personal medical history, and patient preference. Women with a history of certain cancers discuss options carefully with their oncology and menopause care teams. The evidence base supports these hormonal approaches as effective for the majority of women who use them consistently.

Taking the Next Step Toward Comfort and Wellness

Genitourinary syndrome of menopause is common, progressive without treatment, and highly responsive to appropriate care. Bioidentical hormone replacement therapy, particularly low-dose local estrogen and thoughtfully designed systemic regimens when indicated, restores tissue health and relieves the dryness, discomfort, urinary symptoms, and sexual difficulties that characterize GSM. Supportive nonhormonal measures enhance results.

If you have been experiencing these symptoms, know that they are not something you simply have to accept. Open conversation with a clinician experienced in menopausal health can clarify the diagnosis and open effective options. At Glow Health and Wellness we are committed to educating women, validating their experiences, and providing personalized, evidence-informed care that helps restore comfort, confidence, and quality of life. Relief is possible, and it often begins with the decision to seek answers and support.

At Glow Health and Wellness, we're here to guide you every step of the way. Our office is in Destin, FL, and patients in Florida, Arkansas, and Alabama can be seen either in office or via telehealth. Whether you're just beginning to notice changes or seeking advanced management, contact us to reclaim your glow.

SCHEDULE AN APPOINTMENT

Resources:

The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020.

AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. American Urological Association, Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction, and American Urogynecologic Society. 2025.

Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause: A Systematic Review. Annals of Internal Medicine. 2024.

Genitourinary Syndrome of Menopause: Recommendations from the Fifth International Consultation on Sexual Medicine. Sexual Medicine Reviews. 2025.

The Genitourinary Syndrome of Menopause. Menopause journal clinical review.

Systematic reviews and meta-analyses on vaginal estrogen efficacy for lower urinary tract symptoms and GSM symptoms published in Climacteric and related journals.

NAMS Hormone Therapy Position Statement materials addressing genitourinary symptoms.

Leave a comment

Leave this field empty
This form is protected by reCAPTCHA to prevent spam and abuse. Information collected may be processed for security purposes.
Submit

0 Comments

Previous Post

Related Posts

Infographic stating 1 in 6 women reported suicidal thoughts during perimenopause or menopause.

Perimenopause, Depression, and Suicidal Thoughts: Are Hormones to Blame?

October 27, 2026

Woman at desk beside poster about functional medicine and anemia, with laptop, plant, and coffee mug.

Functional Medicine and Anemia: Finding the Root Cause of Low Iron and Fatigue

October 26, 2026

Progesterone vs. Synthetic Progestins: Differences and Mental Health Effects

October 26, 2026

Woman in a hospital gown with a thoughtful expression next to text about hormones and partial hysterectomy.

Do Your Hormones Change After a Partial Hysterectomy If You Keep Your Ovaries?

October 19, 2026

Archive

2026 Jan Feb Mar Apr May Jun Jul Aug Sep Oct
2025 Aug Dec
850-876-4735
SCHEDULE AN APPOINTMENT